Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Jean Hoffman‐Censits(Sidney Kimmel Cancer Center), Tom Powles(Barts Health NHS Trust), Michiel S. van der Heijden(The Netherlands Cancer Institute), Arjun Vasant Balar(NYU Langone Health), Andrea Necchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Nancy A. Dawson(MedStar Georgetown University Hospital), Peter H. O’Donnell(University of Chicago), Ani Sarkis Balmanoukian(Angeles Clinic and Research Institute), Yohann Loriot(Institut Gustave Roussy), Sandy Srinivas(Stanford University), Margitta Retz(Technical University of Munich), Petros Grivas(Cleveland Clinic), Richard W. Joseph(Mayo Clinic in Florida), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Mark T. Fleming(Virginia Oncology Associates), Daniel P. Petrylak(Yale University), José Luis Perez‐Gracia(Clinica Universidad de Navarra), Howard A. Burris(Tennessee Oncology), Daniel Castellano(Research Institute Hospital 12 de Octubre), Christina Canil(Ottawa Hospital), Joaquim Bellmunt(Dana-Farber Cancer Institute), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Dorothee Nickles, Richard Bourgon, Garrett M. Frampton(Foundation Medicine (United States)), Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer(University of Virginia)
The Lancet
March 5, 2016
Cited by 3,710

Abstract


Related Papers